{
    "clinical_study": {
        "@rank": "70620", 
        "arm_group": [
            {
                "arm_group_label": "ARRY-371797 (Dose 1)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ARRY-371797 (Dose 2)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 2 pilot study, involving a 48-week treatment period, designed to test the\n      effectiveness of investigational study drug ARRY-371797 in treating patients with\n      symptomatic genetic dilated cardiomyopathy due to a lamin A/C gene mutation, and to further\n      evaluate the drug's safety. Approximately 12 patients from the US will be enrolled in this\n      study."
        }, 
        "brief_title": "A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy", 
        "condition": "LMNA-Related Dilated Cardiomyopathy", 
        "condition_browse": {
            "mesh_term": [
                "Cardiomyopathy, Dilated", 
                "Cardiomyopathies"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Patients with idiopathic dilated cardiomyopathy and stable New York Heart Association\n             (NYHA) Class II - IIIa congestive heart failure (CHF).\n\n          -  Stable, guidelines-based medical and device therapy, without any CHF hospitalizations\n             or change in heart failure drug dose with \u2265 50% reduction in dose or \u2265 100% increase\n             in dose in the past 3 months.\n\n          -  Left ventricular (LV) end diastolic diameter by trans-thoracic echocardiography of >\n             3.3 cm/m2 (for females) or 3.4 cm/m2 (for males) and/or LV ejection fraction \u2264 45%.\n\n          -  Gene positive for a pathogenic mutation in the LMNA gene, as determined by a\n             CLIA-certified clinical laboratory (mutations including but not limited to:\n             splice-site, non-sense, deletion mutations, a mis-sense mutation in a highly\n             conserved codon, a mis-sense mutation involving a major charge change, a mis-sense\n             mutation previously associated with genetic dilated cardiomyopathy).\n\n          -  Completed distance during six minute walk test of \u2265 100 m and \u2264 350 m within 3 weeks\n             prior to first dose of study drug, and \u2265 100 m and \u2264 400 m on the day before and day\n             of first dose of study drug.\n\n          -  Acceptable hematology, hepatic and renal function laboratory values within 3 weeks\n             prior to first dose of study drug.\n\n          -  Additional criteria exist.\n\n        Key Exclusion Criteria:\n\n          -  Unstable clinical cardiac symptoms requiring unscheduled hospitalization within 60\n             days prior to study start.\n\n          -  Clinically significant coronary artery disease, as per Investigator judgment.\n\n          -  Currently receiving continuous intravenous (IV) inotrope infusion, or presence of a\n             ventricular assist device, or history of prior heart transplantation.\n\n          -  Any of the following within 60 days prior to study start: Myocardial infarction,\n             cardiac surgical procedures, acute coronary syndrome, hemodynamically destabilizing\n             cardiac arrhythmia, serious systemic infection with evidence of septicemia, any major\n             surgical procedure requiring general anesthesia.\n\n          -  Uncorrected, hemodynamically significant primary valvular disease.\n\n          -  Initiation of cardiac resynchronization therapy within 180 days prior to study start.\n\n          -  Likelihood, in the Investigator's opinion, of undergoing cardiac transplantation,\n             left ventricular assist device or other device implantation, or other cardiac surgery\n             within the next 6 months; or of requiring continuous IV inotropic treatment, or\n             referral for hospice or end-of-life treatment.\n\n          -  Active malignancy (except surgically-curative basal cell carcinoma, squamous cell\n             carcinoma, or cervical carcinoma).\n\n          -  Receiving chronic immunosuppressant therapy.\n\n          -  Known positive serology for the human immunodeficiency virus (HIV), active hepatitis\n             B and/or hepatitis C.\n\n          -  Participation in any other investigational study of drugs or devices within 30 days\n             prior to study start.\n\n          -  Additional criteria exist."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02057341", 
            "org_study_id": "ARRAY-797-231"
        }, 
        "intervention": {
            "arm_group_label": [
                "ARRY-371797 (Dose 1)", 
                "ARRY-371797 (Dose 2)"
            ], 
            "description": "multiple dose, single schedule", 
            "intervention_name": "ARRY-371797, p38 inhibitor; oral", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "laminopathy", 
        "lastchanged_date": "May 12, 2014", 
        "location": [
            {
                "contact": {
                    "email": "christina.schmitt@ucdenver.edu", 
                    "last_name": "Christina Schmitt", 
                    "phone": "303-724-2098"
                }, 
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "University of Colorado School of Medicine"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jhoefli1@jhmi.edu", 
                    "last_name": "Jeannette Smith, RN, BSN", 
                    "phone": "410-502-7310"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21205"
                    }, 
                    "name": "Johns Hopkins University"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "ewilson17@partners.org", 
                    "last_name": "Evan Wilson, BS, MPH", 
                    "phone": "724-944-0471"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Brigham and Women's Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "lskatrud@meriter.com", 
                    "last_name": "Lynn Skatrud, RN, CCRC", 
                    "phone": "608-417-2141"
                }, 
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53713"
                    }, 
                    "name": "Meriter Wisconsin Heart"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "last_name": "Array BioPharma Clinical Trial Call Center", 
            "phone": "303-381-6604"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Assess the efficacy of the study drug in terms of change from Baseline in 6-minute walk test.", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02057341"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Assess the efficacy of study drug in terms of left ventricular function.", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "measure": "Assess the efficacy of study drug in terms of right ventricular function.", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "measure": "Assess the safety of study drug in terms of adverse events, clinical laboratory tests and electrocardiograms.", 
                "safety_issue": "Yes", 
                "time_frame": "48 weeks"
            }, 
            {
                "measure": "Characterize the pharmacokinetics (PK) of study drug and metabolites in terms of plasma concentration-time profiles and model-based PK parameters.", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }
        ], 
        "source": "Array BioPharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Array BioPharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}